Publications

Activity of DX-619 compared to other agents against viridians group streptococci, Streptococcus bovis, and Cardiobacterium hominis. by Kosowska-Shick K, Smith K, Bogdanovich T, Ednie LM, Jones RN and Appelbaum PC published in Antimicrob. Agents Chemother. 2006; 50 (12): 4191-4194

Comparison of censored regression and standard regression analyses for modeling relationships between antimicrobial susceptibility and patient- and institution-specific variables. by Hammel JP, Bhavnani SM, Jones RN, Forrest A, Ambrose PG published in Antimicrob. Agents Chemother. 2006; 50 (1): 62-67

Pharmacodynamics of cefprozil against Haemophilus influenzae in an in vitro pharmacodynamic model. by Smith PF, Tsuji B, Booker BM, Forrest A, Bajic S, Kelchlin P, Bhavnani SM, Jones RN and Ambrose PG published in Diagn. Microbiol. Infect. Dis. 2006; 56 (4): 379-386

Carbapenem susceptibility discords among Acinetobacter isolates. by Jones RN, Sader HS, Fritsche TR and Rhomberg PR published in Clin, Infect. Dist. 2006; 42 (1): 158

Multicenter evaluation of the Etest and disk diffusion methods for differentiating daptomycin-susceptible from non-daptomycin-susceptible Staphylococcus aureus isolates. by Jevitt LA, Thorne GM, Traczewski MM, Jones RN, McGowan JE, Tenovera FC and Brown SD published in J. Clin. Microbiol. 2006; 44 (9): 3098-3104

Prevalence of vancomycin-resistant Enterococcus fecal colonization among kidney transplant patients. by Freitas MCS, Pacheco-Silva A, Barbosa D, Silbert S, Sader HS, Sesso R and Camargo LFA published in BMC Inf. Dis. 2006; 6: 133

Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy. by Mariani PG, Sader HS and Jones RN published in J. Antimicrob. Chemother. 2006; 58 (2): 481-483

Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant Gram-positive cocci. by Jones RN, Fritsche TR, Sader HS and Ross JE published in Antimicrob. Agents. Chemother. 2006; 50 (7): 2583-2586

Daptomycin bactericidal activity and correlation between disk and broth microdilution method results in testing of Staphylococcus aureus strains with decreased susceptibility to vancomycin. by Sader HS, Fritsche TR and Jones RN published in Antimicrob. Agents Chemother. 2006; 50 (7): 2330-2336

Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed rormulations and pharmacookinetic relationships: Do the MIC obtained with 2:1 ratio testing accurately reflect activity against β-lactamase-producing strains of Haemophilus Influenzae and Moraxella Catarrhalis? by Pottumarthy, S, Sader, HS, Fritsche, TR, Jones, RN published in Diagn. Microbiol. Infect. Dis. 2005; 53 (3): 225-231

Reproducibility of gemifloxacin and comparison fluoroquinolone MIC results using Sensititre commercial dry-form panels. by Ross JE, Sader HS, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 51 (3): 219-221

Broth microdilution susceptibility testing of Campylobacter jejuni and the determination of quality control ranges for fourteen antimicrobial agents. by McDermott PF, Bodeis-Jones SM, Fritsche TR, Jones RN, Walker RD andCampylobacter Susceptibility Testing Group T. published in J. Clin. Microbiol. 2005; 43 (12): 6136-6138

Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002 – 2003): Contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents. by Pottumarthy S, Fritsche TR, Sader HS, Stilwell MG and Jones RN published in Int. J. Antimicrob. Agents 2005; 25 (4): 282-289

Importance of understanding pharmacokinetic/pharmocodynamic principles in the emergence of resistances, including community-associated Staphylococcus aureus. by Fritsche TR and Jones RN published in J. Drugs Dermatol. 2005; 4 (Suppl 6): s4-s8

Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan. by Bell JA, Turnidge JD, Inoue M, Kohno S, Hirakata Y, Ono Y and Jones RN published in J. Antimicrob. Chemother. 2005; 55 (2):276-278

Identification of a novel cephalosporinase (DHA-3) in Klebsiella pneumoniae isolated in Taiwan. by Wu LT, Hung SW, Chuang YC, Chen HE, Jones RN and Yu WL published in Clin. Microbiol. Inf. 2005; 11 (11): 893-897

Comparative antimicrobial characterization of LBM415 (NVP PDF-713), a new peptide deformylase inhibitor of clinical importance. by Fritsche, TR, Sader, HS, Cleeland, R, Jones, RN published in Antimicrob. Agents Chemother. 2005; 49 (4): 1468-147

Susceptibility testing accuracy of a CTX-M-type extended-spectrum ß-lactamase organism-producing population of Enterobacteriaceae: intermethod analysis for 9 ß-lactams. by Pottumarthy S, Yu Y, Sader HS, Jones RN and Chen M published in Diagn. Microbiol. Infect. Dis. 2005; 53 (2): 131-141

Reproducibility of daptomycin MIC results using dry-form commercial trays with appropriate supplemental calcium content. by Rhomberg PR, Sader HS and Jones RN published in Int. J. Antimicrob. Agents 2005; 25 (3): 274-276

Tigecycline activity tested against 26,474 bloodstream infection isolates: A collection from six continents. by Sader HS, Jones RN, Stilwell MG, Dowzicky MJ and Fritsche TR published in Diagn. Microbiol. Infect. Dis. 2005; 52 (3): 181-186

Quality control guidelines for testing Gram-negative control strains with polymyxin B and colistin (polymyxin E) by standardized methods. by Jones RN, Anderegg TR and Swenson JM published in J. Clin. Microbiol. 2005; 43 (2): 925-927

Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. by Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 52 (3): 187-193

Emerging epidemic of metallo-β-lactamase-mediated resistances. by Jones, R.N., Biedenbach, D.J., Sader, H.S., Fritsche, T.R., Toleman, M.A., Walsh, T.R. published in Diagn. Microbiol. Infect. Dis. 2005; 51 (2): 77-84

Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000 – 2004). by Fritsche, TR, Sader HS, Stilwell MG, Dowzicky MJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 52 (3): 195-201

Antimicrobial activity of LBM415 (NVP PDF-713) tested against pathogenic Neisseria spp. (Neisseria gonorrhoeae and Neisseria meningitidis). by Jones RN, Sader HS and Fritsche TR published in Diagn. Microbiol. Infect. Dis. 2005; 51 (2): 139-141

Activity of tigecycline tested against a global collection of Enterobacteriaceae, including tetracycline-resistant isolates. by Fritsche TR, Strabala PA, Sader HS, Dowzicky MJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 52 (3):209-213

Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli. by Sader HS and Jones RN published in Int. J. Antimicrob. Agents 2005; 25 (2):95-109

Re-evaluation of Enterobacteriaceae MIC/disk diffusion zone diameter regression scattergrams for bine beta-lactams: Adjustments of breakpoints for strains producing extended-spectrum beta-lactamases. by Jones, R.N., Craig, W.A., Ambrose, P.G., Dudley, M.N., Pottumarthy, S. published in Diagn. Microbiol. Infect. Dis. 2005; 52 (3): 235-246

Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States. by Bhavnani SM, Hammel JP, Jones RN and Ambrose PG published in Diagn. Microbiol. Infect. Dis. 2005; 51 (1): 31-37

Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains. by Sader HS, Fritsche TR, Kaniga K, Ge Y, Jones RN published in Antimicrob. Agents Chemother. 2005; 49 (8): 3501-3512

Cefdinir activity against contemporary North American isolates from community-acquired urinary tract infections. by Sader HS, Biedenbach DJ, Streit JM and Jones RN published in Int. J. Antimicrob. Agents 2005; 25 (1): 89-92

IMPs, VIMs and SPMs: The diversity of metallo-β-lactamases produced by carbapenem-resistant Pseudomonas aeruginosa in a Brazilian hospital. by Sader HS, Reis AO, Silbert S, Gales AC published in Clin. Microbiol. Infect. 2005; 11 (1): 73-76

Therapeutic options among broad-spectrum β-lactams for infections caused by levofloxacin-nonsusceptible Streptococcus pneumoniae. by Jones RN, Fritsche TR and Sader HS published in Diagn. Microbiol. Infect. Dis. 2005; 52 (2): 129-133

Candidatus Protochlamydia amoebophilia’, an endosymbiont of Acanthamoeba spp. by Collingro A, Toenshoff EA, Taylor MW, Fritsche TR, Wagner M and Horn M published in Int. J. Sys. Evol. Microbiol. 2005; 55 (Pt 5): 1863-1866

Re-evaluation of the cefepime minimal inhibitory concentrations and disk diffusion test zone diameter relationship for a worldwide collection of Enterobacteriaceae enriched for extended-spectrum beta-lactamase-producing organisms. by Pottumarthy S, Deshpande LM, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 52 (2): 95-99

Dalbavancin activity against selected populations of antimicrobial-resistant Gram-positive pathogens. by Streit, J.M., Sader, H.S., Fritsche, T.R., Jones, R.N. published in Diagn. Microbiol. Infect. Dis. 2005; 53 (4): 307-310

Reproducibility assessment of tigecycline MIC results by broth microdilution methods using commercially prepared dry-form panels. by Rhomberg PR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2005; 52 (1): 67-69

Activity of faropenem tested against Neisseria gonorrhoeae isolates including fluoroquinolone-resistant strains. by Jones RN, Critchley IA, Whittington WL, Janjic N and Pottumarthy S published in Diagn. Microbiol. Infect. Dis. 2005; 53 (4): 311-317

Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various β-lactamase resistance mechanisms. by Jones, R.N., Sader, H.S., Fritsche, T.R. published in Diagn. Microbiol. Infect. Dis. 2005; 52 (1): 71-74

Quality control guidelines for susceptibility testing of retapamulin (SB-275833) by reference and standardized methods. by Ross JE and Jones RN published in J. Clin. Microbiol. 2005; 43 (12): 6212-6213

Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis. by Streit, J.M., Steenbergen, J.N., Thorne, G.M., Alder, J., Jones, R.N. published in J. Antimicrob. Chemother. 2005; 55 (4): 574-578

Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. by Deshpande L, Rhomberg PR, Fritsche TR, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 50 (1): 73-75

Worldwide assessment of dalbavancin activity and spectrum against over 6,000 clinical isolates. by Streit JM, Fritsche TR, Sader HS and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 48 (2): 137-143

Commercial broth microdilution panel validation and reproducibility trials for NVP PDF-713 (LBM415), a novel inhibitor of bacterial peptide deformylase. by Fritsche TR, Moet GJ, Jones RN published in Clin. Microbiol. Infect. 2004; 10 (9): 857-860

Disk diffusion quality control guidelines for NVP PDF-713: A novel peptide deformylase inhibitor. by Anderegg TR, Jones RN, The Quality Control Working Group published in Diagn. Microbiol. Infect. Dis. 2004; 48 (1): 55-57

Results of two worldwide surveys into physician awareness and perceptions of extended-spectrum beta-lactamases. by Goossens H, Malhotra-Kumar S, Eraksoy H, Unal S, Grabein B, Masterton R, Mendes C, Garcia-Rodriguez J-A, Russo G and Jones RN published in Clin. Microbiol. Infect. 2004; 10 (8):760-762

Validation of commercial dry-form broth microdilution panels and test reproducibility for susceptibility testing of dalbavancin, a new very long-acting glycopeptide. by Jones RN, Streit JM and Fritsche TR published in Int. J. Antimicrob. Agents. 2004; 23 (2): 197-199

Potency and spectrum reevaluation of cefdinir tested against pathogens causing skin and soft tissue infections: A sample of North American isolates. by Sader HS, Streit JM, Fritsche TR and Jones RN published in Diagn. Microbiol. Infect. Dis. 2004; 49 (4): 283-287

Preliminary susceptibility testing guidelines for AZD2563, a long-acting oxazolidinone. by Anderegg TR and Jones RN published in Int. J. Antimicrob. Agents 2004; 23 (1): 6-10

Activities of doripenem (S-4661) against drug-resistant clinical pathogens. by Jones RN, Huynh HK, Biedenbach DJ published in Antimicrob. Agents. Chemother. 2004; 48 (8): 3136-3140